NERLYNX Available From Onco360

Onco360 Chosen for Limited Distribution Pharmacy Network

Onco360, the nation’s largest independent Oncology Pharmacy has been selected to be in the limited distribution network for Puma Biotechnology, Inc.’s new product, NERLYNX™ (neratinib), a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA). NERLYNX is indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

Onco360 President and CEO, Paul Jardina said “NERLYNX provides an innovative new therapy to reduce the recurrence of breast cancer, which is the leading concern for recovering breast cancer patients and their families. We are pleased to be selected to the limited distribution pharmacy network for this highly anticipated medication. Onco360’s patient-centric approach to cancer care continues to be attractive to biopharmaceutical companies like Puma Biotechnology, who focus on pioneering new treatments in oncology. We are excited to add NERLYNX to our limited distribution portfolio of products, and Onco360 will provide outstanding care to patients in need of this breakthrough therapy.”

The most common adverse reactions associated with NERLYNX (≥5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased and urinary tract infection. For prescribing information, including important safety and patient information, please visit: NERLYNX.com.

NERLYNX is immediately available for prescription order from Onco360.